Immune Response BioPharma, Inc.

NEW YORK, NY · Founded 2011 · CIK 0001524679 · Biotech · Private

Immunotherapeutic biologics for cancer and infectious disease treatment

immuneresponsebiopharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.0B
3 Form D · Aug 2012
170 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$10,000,000
Private capital raisedForm D · SEC$1,000,000,000
Private capital raisedForm D · SEC$1,000,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2710ISOPRENE PHARMACEUTICALS, INC.——
2711KATHERA BIOSCIENCE INC.——
2712ENCUE INC.——
2713Immune Response BioPharma, Inc.—$1.0B
2714Foghorn Therapeutics——
2715COGNOSCI, INC.——
2716IMPLICYTE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • David BuswellExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.